Skip to main content
Erschienen in: Supportive Care in Cancer 9/2015

01.09.2015 | Original Article

Impact of time to antibiotics on outcomes of chemotherapy-induced febrile neutropenia

verfasst von: Byuk Sung Ko, Shin Ahn, Yoon-Seon Lee, Won Young Kim, Kyung Soo Lim, Jae-Lyun Lee

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to determine the relationship between the time to antibiotic administration and patients’ outcomes of febrile neutropenia (FN). We also investigated the relationship between the time to antibiotics and mortality rates in a subgroup of patients with bacteremia or severe sepsis or septic shock.

Methods

From the Neutropenic Fever Registry, we analyzed 1001 consecutive FN episodes diagnosed from November 1, 2011, to August 31, 2014. Timing cutoffs for antibiotics included the following: ≤1 vs. >1 h, ≤2 vs. >2 h, ≤3 vs. >3 h, and ≤4 vs. >4 h. Multivariate logistic regression was used to adjust for potential confounders in the association between timing intervals and outcomes of FN episodes.

Results

The median length of time from triage to antibiotics was 140 min (interquartile range, 110–180 min). At each time cutoff, the time from triage to antibiotic administration was not significantly associated with FN outcomes after adjusting for potential confounders. Antibiotic timing was not significantly associated with complication rates in overall FN episodes. We failed to find a significant relationship between antibiotic timing and mortality in FN episodes with severe sepsis or septic shock or with bacteremia. Procalcitonin concentration and the Multinational Association for Supportive Care in Cancer (MASCC) risk index score were found to be more crucial determinants of outcomes in patients with FN.

Conclusions

The time to antibiotic administration is not a major factor in FN outcomes.
Literatur
1.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of A (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):e56–93PubMedCrossRef Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of A (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):e56–93PubMedCrossRef
2.
Zurück zum Zitat de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, Group EGW (2010) Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 21(Suppl 5):v252–256PubMedCrossRef de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, Group EGW (2010) Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 21(Suppl 5):v252–256PubMedCrossRef
3.
Zurück zum Zitat Tam CS, O'Reilly M, Andresen D, Lingaratnam S, Kelly A, Burbury K, Turnidge J, Slavin MA, Worth LJ, Dawson L, Thursky KA (2011) Use of empiric antimicrobial therapy in neutropenic fever. Australian consensus guidelines 2011 steering committee. Intern Med J 41(1b):90–101PubMedCrossRef Tam CS, O'Reilly M, Andresen D, Lingaratnam S, Kelly A, Burbury K, Turnidge J, Slavin MA, Worth LJ, Dawson L, Thursky KA (2011) Use of empiric antimicrobial therapy in neutropenic fever. Australian consensus guidelines 2011 steering committee. Intern Med J 41(1b):90–101PubMedCrossRef
4.
Zurück zum Zitat Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA (2008) Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 87(2):139–145PubMedCrossRef Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA (2008) Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 87(2):139–145PubMedCrossRef
5.
Zurück zum Zitat Lynn JJ, Chen KF, Weng YM, Chiu TF (2013) Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Hematol Oncol 31(4):189–196PubMedCrossRef Lynn JJ, Chen KF, Weng YM, Chiu TF (2013) Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Hematol Oncol 31(4):189–196PubMedCrossRef
6.
Zurück zum Zitat Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shofer FS, Goyal M (2010) Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38(4):1045–1053PubMedCrossRef Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shofer FS, Goyal M (2010) Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38(4):1045–1053PubMedCrossRef
7.
Zurück zum Zitat Gross PA (2006) Hypotension and mortality in septic shock: the “golden hour. Crit Care Med 34(6):1819–1820PubMedCrossRef Gross PA (2006) Hypotension and mortality in septic shock: the “golden hour. Crit Care Med 34(6):1819–1820PubMedCrossRef
8.
Zurück zum Zitat Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36(1):296–327PubMedCrossRef Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36(1):296–327PubMedCrossRef
9.
Zurück zum Zitat Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative G (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19):1368–1377PubMedCrossRef Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative G (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19):1368–1377PubMedCrossRef
10.
Zurück zum Zitat Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E (2008) Management of febrile neutropenia in solid tumours and lymphomas using the multinational association for supportive care in cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 16(5):485–491PubMedCrossRef Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E (2008) Management of febrile neutropenia in solid tumours and lymphomas using the multinational association for supportive care in cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 16(5):485–491PubMedCrossRef
11.
Zurück zum Zitat Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, Choi JH (2011) Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 26(2):220–252PubMedCentralPubMedCrossRef Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, Choi JH (2011) Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 26(2):220–252PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMed
13.
Zurück zum Zitat Ahn S, Lee YS, Chun YH, Kwon IH, Kim W, Lim KS, Kim TW, Lee KH (2011) Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 19(8):1151–1158PubMedCrossRef Ahn S, Lee YS, Chun YH, Kwon IH, Kim W, Lim KS, Kim TW, Lee KH (2011) Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 19(8):1151–1158PubMedCrossRef
14.
Zurück zum Zitat Ahn S, Lee YS, Lim KS, Lee JL (2013) Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 21(8):2303–2308PubMedCrossRef Ahn S, Lee YS, Lim KS, Lee JL (2013) Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 21(8):2303–2308PubMedCrossRef
15.
Zurück zum Zitat Ahn S, Lee YS (2012) Predictive factors for poor prognosis febrile neutropenia. Curr Opin Oncol 24(4):376–380PubMedCrossRef Ahn S, Lee YS (2012) Predictive factors for poor prognosis febrile neutropenia. Curr Opin Oncol 24(4):376–380PubMedCrossRef
16.
Zurück zum Zitat Szwajcer D, Czaykowski P, Turner D (2011) Assessment and management of febrile neutropenia in emergency departments within a regional health authority—a benchmark analysis. Curr Oncol 18(6):280–284PubMedCentralPubMedCrossRef Szwajcer D, Czaykowski P, Turner D (2011) Assessment and management of febrile neutropenia in emergency departments within a regional health authority—a benchmark analysis. Curr Oncol 18(6):280–284PubMedCentralPubMedCrossRef
17.
18.
Zurück zum Zitat Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG (2004) Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 164(6):637–644PubMedCrossRef Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG (2004) Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 164(6):637–644PubMedCrossRef
19.
Zurück zum Zitat Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J (2003) Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 31(10):2478–2482PubMedCrossRef Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J (2003) Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 31(10):2478–2482PubMedCrossRef
20.
Zurück zum Zitat Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278(23):2080–2084PubMedCrossRef Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278(23):2080–2084PubMedCrossRef
21.
Zurück zum Zitat Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34(6):1589–1596PubMedCrossRef Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34(6):1589–1596PubMedCrossRef
22.
Zurück zum Zitat Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA (2003) Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 123(5):1615–1624PubMedCrossRef Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA (2003) Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 123(5):1615–1624PubMedCrossRef
Metadaten
Titel
Impact of time to antibiotics on outcomes of chemotherapy-induced febrile neutropenia
verfasst von
Byuk Sung Ko
Shin Ahn
Yoon-Seon Lee
Won Young Kim
Kyung Soo Lim
Jae-Lyun Lee
Publikationsdatum
01.09.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2645-5

Weitere Artikel der Ausgabe 9/2015

Supportive Care in Cancer 9/2015 Zur Ausgabe

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.